Compare WEST & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | DRUG |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | 1393 | N/A |
| Industry | Beverages (Production/Distribution) | Pharmaceuticals and Biotechnology |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.4M | 744.9M |
| IPO Year | N/A | 2020 |
| Metric | WEST | DRUG |
|---|---|---|
| Price | $8.08 | $73.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 434.5K | 229.3K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.27 | N/A |
| Revenue Next Year | $10.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.59 | $32.50 |
| 52 Week High | $10.19 | $123.75 |
| Indicator | WEST | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 49.29 |
| Support Level | $7.73 | $71.39 |
| Resistance Level | $8.54 | $77.16 |
| Average True Range (ATR) | 0.43 | 4.06 |
| MACD | 0.10 | -0.21 |
| Stochastic Oscillator | 77.36 | 30.38 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.